Bacteriophages and Lysins in Biofilm Control
- PMID: 32125643
- PMCID: PMC7198674
- DOI: 10.1007/s12250-019-00192-3
Bacteriophages and Lysins in Biofilm Control
Abstract
To formulate the optimal strategy of combatting bacterial biofilms, in this review we update current knowledge on the growing problem of biofilm formation and its resistance to antibiotics which has spurred the search for new strategies to deal with this complication. Based on recent findings, the role of bacteriophages in the prevention and elimination of biofilm-related infections has been emphasized. In vitro, ex vivo and in vivo biofilm treatment models with single bacteriophages or phage cocktails have been compared. A combined use of bacteriophages with antibiotics in vitro or in vivo confirms earlier reports of the synergistic effect of these agents in improving biofilm removal. Furthermore, studies on the application of phage-derived lysins in vitro, ex vivo or in vivo against biofilm-related infections are encouraging. The strategy of combined use of phage and antibiotics seems to be different from using lysins and antibiotics. These findings suggest that phages and lysins alone or in combination with antibiotics may be an efficient weapon against biofilm formation in vivo and ex vivo, which could be useful in formulating novel strategies to combat bacterial infections. Those findings proved to be relevant in the prevention and destruction of biofilms occurring during urinary tract infections, orthopedic implant-related infections, periodontal and peri-implant infections. In conclusion, it appears that most efficient strategy of eliminating biofilms involves phages or lysins in combination with antibiotics, but the optimal scheme of their administration requires further studies.
Keywords: Antibiotics; Bacteriophages; Biofilm; Chronic diseases; Lysins.
Conflict of interest statement
A Górski and B Weber-Dąbrowska are co-inventors of patents owned by the Hirszfeld Institute of Immunology and Experimental Therapy and covering phage preparations. M Łusiak-Szelachowska declares that she has no conflict of interest.
Similar articles
-
Anti-biofilm activity of bacteriophages and lysins in chronic rhinosinusitis.Acta Virol. 2021;65(2):127-140. doi: 10.4149/av_2021_203. Acta Virol. 2021. PMID: 34130464
-
Use of polyvalent bacteriophages to combat biofilm of Proteus mirabilis causing catheter-associated urinary tract infections.J Appl Microbiol. 2018 Nov;125(5):1253-1265. doi: 10.1111/jam.14026. Epub 2018 Jul 18. J Appl Microbiol. 2018. PMID: 29924909
-
The use of bacteriophages to biocontrol oral biofilms.J Biotechnol. 2017 May 20;250:29-44. doi: 10.1016/j.jbiotec.2017.01.002. Epub 2017 Jan 17. J Biotechnol. 2017. PMID: 28108235 Review.
-
Big Impact of the Tiny: Bacteriophage-Bacteria Interactions in Biofilms.Trends Microbiol. 2019 Sep;27(9):739-752. doi: 10.1016/j.tim.2019.04.006. Epub 2019 May 22. Trends Microbiol. 2019. PMID: 31128928 Review.
-
Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials.Front Immunol. 2018 Oct 16;9:2252. doi: 10.3389/fimmu.2018.02252. eCollection 2018. Front Immunol. 2018. PMID: 30459750 Free PMC article. Review.
Cited by
-
Efficacy and Experience of Bacteriophages in Biofilm-Related Infections.Antibiotics (Basel). 2024 Jan 26;13(2):125. doi: 10.3390/antibiotics13020125. Antibiotics (Basel). 2024. PMID: 38391511 Free PMC article. Review.
-
A new Rogue-like Escherichia phage UDF157lw to control Escherichia coli O157:H7.Front Microbiol. 2024 Jan 22;14:1302032. doi: 10.3389/fmicb.2023.1302032. eCollection 2023. Front Microbiol. 2024. PMID: 38318127 Free PMC article.
-
Phage therapy in lung infections caused by multidrug-resistant Pseudomonas aeruginosa - A literature review.Eur J Microbiol Immunol (Bp). 2024 Jan 23;14(1):1-12. doi: 10.1556/1886.2023.00060. Print 2024 Feb 23. Eur J Microbiol Immunol (Bp). 2024. PMID: 38261031 Free PMC article. Review.
-
Controlling of foodborne pathogen biofilms on stainless steel by bacteriophages: A systematic review and meta-analysis.Biofilm. 2023 Dec 17;7:100170. doi: 10.1016/j.bioflm.2023.100170. eCollection 2024 Jun. Biofilm. 2023. PMID: 38234712 Free PMC article.
-
Microbiome as a biomarker and therapeutic target in pancreatic cancer.BMC Microbiol. 2024 Jan 5;24(1):16. doi: 10.1186/s12866-023-03166-4. BMC Microbiol. 2024. PMID: 38183010 Free PMC article. Review.
References
-
- Abedon ST. Bacteriophage-mediated biocontrol of wound infections, and ecological exploitation of biofilms by phages. In: Shiffman MA, Low M, editors. Recent clinical techniques, results, and research in wounds. Berlin: Springer; 2018. pp. 1–38.
-
- Akanda ZZ, Taha M, Abdelbary H. Current review-The rise of bacteriophage as a unique therapeutic platform in treating peri-prosthetic joint infections. J Orthop Res. 2018;36:1051–1060. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
